Ferroptosis-IN-25 

Ferroptosis-IN-25, Trolox (HY-101445) derivative, is a selective ferroptosis inhibitor. Ferroptosis-IN-25 selectively inhibits ferroptosis by scavenging ROS and suppressing lipid peroxidation independently of glutathion. Ferroptosis-IN-25 reduces corneal neovascularization and edema in murine corneal alkali burn models via topical administration.Ferroptosis-IN-25 can be used for the research of ocular surface diseases^[1].

Ferroptosis-IN-25 (Compound 20) (24 h) potently inhibits RSL3 (HY-100218A)-induced ferroptosis in HT22 cells with an IC₅₀ of 0.036 μM^[1].
Ferroptosis-IN-25 (24 h) exhibits moderate cytotoxicity in HT22 cells with a TC₅₀ of 45 μM, yielding a high safety index of 1125^[1].
Ferroptosis-IN-25 (30 min) demonstrates potent DPPH radical scavenging activity with an EC₅₀ of 5.4 μM in a cell-free assay^[1].
Ferroptosis-IN-25 has low peroxyl radical quenching capacity with an ORAC value of 0.34 Trolox (HY-101445) equivalents in a cell-free assay^[1].
Ferroptosis-IN-25 (24 h) potently inhibits glutamate-induced oxytosis in HT22 cells with an IC₅₀ of 0.15 μM^[1].
Ferroptosis-IN-25 (0.025-0.2 μM; 8 h) significantly reduces intracellular ROS accumulation in glutamate-treated HT22 cells, without restoring depleted GSH levels^[1].
Ferroptosis-IN-25 (24 h) potently inhibits RSL3-induced ferroptosis in HCECs with an IC₅₀ of 0.052 μM^[1].
Ferroptosis-IN-25 (8 h) significantly inhibits RSL3-induced lipid peroxidation in HCECs^[1].
Ferroptosis-IN-25 (24 h) does not protect HT-29 cells against TSZ-induced necroptosis, demonstrating selective activity for ferroptosis over necroptosis^[1].
Ferroptosis-IN-25 (24 h) does not protect HCECs against STS-induced apoptosis, demonstrating selective activity for ferroptosis over apoptosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ferroptosis-IN-25 (Compound 20) (50-800 μM; topical eye drops; twice daily; 14 days) significantly reduces alkali burn-induced corneal neovascularization, reduces corneal edema and dose-dependently restores corneal epithelial GPX4 expression in C57BL/6 J mice^[1].
Ferroptosis-IN-25 (50-800 μM; topical eye drops; twice daily; 14 days) shows a favorable safety profile in healthy C57BL/6 J mice, with no significant corneal damage or IOP changes observed at effective therapeutic doses^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

365.43

C₂₁H₂₃N₃O₃

O=C(NC1=CC=C(C=NN2)C2=C1)C3(C)OC4=C(C)C(C)=C(O)C(C)=C4CC3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wang J, et al. Discovery of Trolox amide derivatives as potent membrane-targeted ferroptosis inhibitors for corneal injury therapy. Eur J Med Chem. 2026;313:118880.